Citation: | ZHONG Cheng, ZHANG Yang, CHU Ziang, QIAN Hong. Therapeutic Effect of Savolitinib in Patients with Stage Ⅲ/Ⅳ Non-small Cell Lung Cancer[J]. Cancer Research on Prevention and Treatment, 2024, 51(3): 191-194. DOI: 10.3971/j.issn.1000-8578.2024.23.0909 |
To analyze therapeutic effect of savolitinib in patients with stage Ⅲ/Ⅳ non-small cell lung cancer (NSCLC).
A total of 95 patients with MET 14 exon (METex14) jumping mutation in stage Ⅲ/Ⅳ NSCLC were divided into a control group (47 cases) and an observation group (48 cases) through a random-number table method. The patients in the control group were treated with crizotinib, whereas those in the observation group were treated with savolitinib. The clinical efficacy and incidence of toxic side effects in both groups were evaluated through a chi-square test, and survival was evaluated through Kaplan-Meier survival analysis.
Compared with control group (31.91% and 70.21%), the objective response rate and disease control rate of the observation group were 52.08% and 87.50%, respectively (P<0.05). According to Kaplan-Meier survival analysis, the overall survival and progression free survival rates in the observation group were higher than those in the control group (Log rank χ2=8.003, 4.528; P=0.005, 0.033). No statistically significant difference in the degree of toxic side effects was found between the groups (P>0.05).
Savolitinib can improve the efficacy of treatment for stage Ⅲ/Ⅳ METex14 skip mutation NSCLC patients, prolong survival, enhance the tolerance of patients to savolitinib, and facilitate the management of adverse reactions.
Competing interests: The authors declare that they have no competing interests.
[1] |
王秋, 林川. ALDH1和AQP-5蛋白在非小细胞肺癌组织中的表达及与病理学参数, 预后的关系[J]. 河北医药, 2021, 43(4): 548-551. [Wang Q, Lin C. Expression of ALDH1 and AQP-5 proteins in NSCLC tissues and their relationship with clinical pathological parameters and prognosis of patients[J]. Hebei Yi Yao, 2021, 43(4): 548-551.]
Wang Q, Lin C. Expression of ALDH1 and AQP-5 proteins in NSCLC tissues and their relationship with clinical pathological parameters and prognosis of patients[J]. Hebei Yi Yao, 2021, 43(4): 548-551.
|
[2] |
Xu H, Wang J, Al-Nusaif M, et al. CCL2 promotes metastasis and epithelial-mesenchymal transition of non-small cell lung cancer via PI3K/Akt/mTOR and autophagy pathways[J]. Cell Prolif, 2023, 18: e13560.
|
[3] |
Gohlke L, Alahdab A, Oberhofer A, et al. Loss of Key EMT-Regulating miRNAs Highlight the Role of ZEB1 in EGFR Tyrosine Kinase Inhibitor-Resistant NSCLC[J]. Int J Mol Sci, 2023, 24(19): 14742.
|
[4] |
Mahrous M, Omar Jebriel A, Allehebi A, et al. Consensus Recommendations for the Diagnosis, Biomarker Testing, and Clinical Management of Advanced or Metastatic Non-small Cell Lung Cancer With Mesenchymal-Epithelial Transition Exon 14 Skipping Mutations in the Middle East, Africa, and Russia[J]. Cureus, 2023, 15(7): e41992.
|
[5] |
郭宗儒. 我国自行研制的抗癌药物赛沃替尼[J]. 药学学报, 2022, 57(3): 839-844. [Guo ZR. China's self-developed anti-cancer drug, Sevotinib[J]. Yao Xue Xue Bao, 2022, 57(3): 839-844.]
Guo ZR. China's self-developed anti-cancer drug, Sevotinib[J]. Yao Xue Xue Bao, 2022, 57(3): 839-844.
|
[6] |
葛均波, 徐永健, 王辰. 内科学[M]. 第9版. 北京: 人民卫生出版社, 2018: 75-86. [Ge JB, Xu YJ, Wang C. Internal medicine[M]. 9th edition. Beijing: People's Medical Publishing House Co. , Ltd, 2018: 75-86.]
Ge JB, Xu YJ, Wang C. Internal medicine[M]. 9th edition. Beijing: People's Medical Publishing House Co. , Ltd, 2018: 75-86.
|
[7] |
曹珍, 李增军, 单军奇, 等. 调控肝细胞生长因子受体c-Met表达对结肠癌细胞生物学潜能的影响[J]. 中华肿瘤防治杂志, 2022, 29(11): 816-823. [Cao Z, Li ZJ, Shan JQ, et al. Effect of regulation of hepatocyte growth factor receptor c-Met expression on the biological potentiality of colon cancer cells[J]. Zhonghua Zhong Liu Fang Zhi Za Zhi, 2022, 29(11): 816-823.]
Cao Z, Li ZJ, Shan JQ, et al. Effect of regulation of hepatocyte growth factor receptor c-Met expression on the biological potentiality of colon cancer cells[J]. Zhonghua Zhong Liu Fang Zhi Za Zhi, 2022, 29(11): 816-823.
|
[8] |
陈恒屹, 何勇. 肝细胞生长因子/间质上皮转化因子信号通路与非小细胞肺癌靶向治疗耐药的关系及机制研究进展[J]. 中国医学科学院学报, 2021, 43(2): 259-264. [Chen HY, He Y. Research Progress in Hepatocyte Growth Factor/Mesenchymal-epithelial Transition Factor Signaling Pathway: Effects and Mechanisms on Resistance to Targeted Therapy for Non-small Cell Lung Cancer[J]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao, 2021, 43(2): 259-264.]
Chen HY, He Y. Research Progress in Hepatocyte Growth Factor/Mesenchymal-epithelial Transition Factor Signaling Pathway: Effects and Mechanisms on Resistance to Targeted Therapy for Non-small Cell Lung Cancer[J]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao, 2021, 43(2): 259-264.
|
[9] |
Recondo G, Che J, Jänne PA, et al. Targeting MET dysregulation in cancer[J]. Cancer Discov, 2020, 10(7): 922-934. doi: 10.1158/2159-8290.CD-19-1446
|
[10] |
周晔, 于雁. MET14外显子跳跃突变与非小细胞肺癌[J]. 国际肿瘤学杂志, 2021, 48(6): 366-369. [Zhou Y, Yu Y. MET14 exon skipping mutation and non-small cell lung cancer[J]. Guo Ji Zhong Liu Xue Za Zhi, 2021, 48(6): 366-369.]
Zhou Y, Yu Y. MET14 exon skipping mutation and non-small cell lung cancer[J]. Guo Ji Zhong Liu Xue Za Zhi, 2021, 48(6): 366-369.
|
[11] |
钱伟玲, 吴沙沙, 赵红梅, 等. 克唑替尼胶囊联合NP方案治疗晚期非小细胞肺癌的效果及对血清NSE, CEA, Cyfra21-1水平的影响[J]. 临床误诊误治, 2022, 35(10): 26-32. [Qian WL, Wu SS, Zhao HM, et al. Effect of Crizotinib Capsules Combined with NP Regimen in the Treatment of Advanced Non-small Cell Lung Cancer and Its Influence on the Levels of Serum NSE, CEA and Cyfra21-1[J]. Lin Chuang Wu Zhen Wu Zhi, 2022, 35(10): 26-32.]
Qian WL, Wu SS, Zhao HM, et al. Effect of Crizotinib Capsules Combined with NP Regimen in the Treatment of Advanced Non-small Cell Lung Cancer and Its Influence on the Levels of Serum NSE, CEA and Cyfra21-1[J]. Lin Chuang Wu Zhen Wu Zhi, 2022, 35(10): 26-32.
|
[12] |
Engstrom LD, Aranda R, Lee M, et al. Glesatinib exhibits antitumor activity in lung cancer models and patients harboring MET exon 14 mutations and overeomes mutation-mediated resistance to type I MET inbibitors in nonclinical models[J]. Clin Cancer Res, 2017, 23(21): 6661-6672.
|
[13] |
Barry E, Maloney E, Henry R, et al. Abstract 1150: Targeting MET Exon 14 mutations with the selective small molecule inhibitor Savolitinib[J]. Cancer Res, 2016, 76(14 Suppl): 1150.
|
[14] |
刘海旺, 张宏旭, 刘燃, 等. 肝细胞生长因子/酪氨酸蛋白激酶MET信号通路与乳腺癌侵袭转移的相关性分析[J]. 安徽医药, 2021, 25(3): 516-519. [Liu HW, Zhang HX, Liu R, et al. Analysis of correlation between HGF/c-met signaling pathway and invasion and metastasis of breast cancer[J]. Anhui Yi Yao, 2021, 25(3): 516-519.]
Liu HW, Zhang HX, Liu R, et al. Analysis of correlation between HGF/c-met signaling pathway and invasion and metastasis of breast cancer[J]. Anhui Yi Yao, 2021, 25(3): 516-519.
|
[15] |
Jones RDO, Grondine M, Borodovsky A, et al. A pharmacokinetic-pharmacodynamic model for the MET tyrosine kinase inhibitor, savolitinib, to explore target inhibition requirements for anti-tumour activity[J]. Br J Pharmacol, 2021, 178(3): 600-613. doi: 10.1111/bph.15301
|
[16] |
Huang G, Liu X, Jiang T, et al. Luteolin overcomes acquired resistance to osimertinib in non-small cell lung cancer cells by targeting the HGF-MET-Akt pathway[J]. Am J Cancer Res, 2023, 13(9): 4145-4162.
|